An Open-label, 2-part Study Designed to Assess the Absolute Bioavailability of CORT118335 and Determine the Mass Balance Recovery, Absorption, Metabolism and Elimination, and Metabolite Profile and Identification of Metabolite Structures of [14C]-CORT118335 in Healthy Male Subjects
Latest Information Update: 13 Jun 2019
At a glance
- Drugs Miricorilant (Primary) ; Miricorilant (Primary)
- Indications Metabolic disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Weight gain
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
- 10 Jun 2019 Status changed from recruiting to completed.
- 25 Mar 2019 New trial record